Instituto de Investigación Sanitaria La Fe-ko ikertzaileekin lankidetzan egindako argitalpenak (17)

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. Erratum to: Mapping the human genetic architecture of COVID-19 (Nature, (2021), 600, 7889, (472-477), 10.1038/s41586-021-03767-x)

    Nature

2022

  1. Changes in the management of IBD patients since the onset of COVID-19 pandemic. A path toward the implementation of telemedicine in Spain?

    Gastroenterologia y Hepatologia, Vol. 45, Núm. 9, pp. 697-705

  2. Consensus Statement on Hemostatic Management, Anticoagulation, and Antiplatelet Therapy in Liver Transplantation

    Transplantation, Vol. 106, Núm. 6, pp. 1123-1131

  3. Novel genes and sex differences in COVID-19 severity

    Human molecular genetics, Vol. 31, Núm. 22, pp. 3789-3806

2021

  1. Extraintestinal Manifestations in Patients with Inflammatory Bowel Disease: Study Based on the ENEIDA Registry

    Digestive Diseases and Sciences, Vol. 66, Núm. 6, pp. 2014-2023

  2. Incidence, clinical characteristics and management of inflammatory bowel disease in spain: Large-scale epidemiological study

    Journal of Clinical Medicine, Vol. 10, Núm. 13

  3. Mapping the human genetic architecture of COVID-19

    Nature, Vol. 600, Núm. 7889, pp. 472-477

2020

  1. Prospective, study comparing the accuracy of two different stool antigen tests (Premier Platinum HpSA and novel ImmunoCard STAT! rapid test) for the diagnosis of Helicobacter pylori infection

    Gastroenterologia y Hepatologia, Vol. 43, Núm. 3, pp. 117-125

2019

  1. Hemostatic spray powder TC-325 for GI bleeding in a nationwide study: survival and predictors of failure via competing risks analysis

    Gastrointestinal Endoscopy, Vol. 90, Núm. 4, pp. 581-590.e6

2017

  1. Effectiveness of adalimumab for the treatment of ulcerative colitis in clinical practice: comparison between anti-tumour necrosis factor-naïve and non-naïve patients

    Journal of Gastroenterology, Vol. 52, Núm. 7, pp. 788-799

  2. Erratum to: Effectiveness of adalimumab for the treatment of ulcerative colitis in clinical practice: comparison between anti-tumour necrosis factor-naïve and non-naïve patients (J Gastroenterol, 10.1007/s00535-016-1274-1)

    Journal of Gastroenterology

2016

  1. The Fanconi anemia DNA damage repair pathway in the spotlight for germline predisposition to colorectal cancer

    European Journal of Human Genetics, Vol. 24, Núm. 10, pp. 1501-1505

2015

  1. Whole-exome sequencing identifies rare pathogenic variants in new predisposition genes for familial colorectal cancer

    Genetics in Medicine, Vol. 17, Núm. 2, pp. 131-142

2014

  1. New genes emerging for colorectal cancer predisposition

    World Journal of Gastroenterology, Vol. 20, Núm. 8, pp. 1961-1971

2013

  1. Safety of thiopurine therapy in inflammatory bowel disease: Long-term follow-up study of 3931 patients

    Inflammatory Bowel Diseases, Vol. 19, Núm. 7, pp. 1404-1410

2011

  1. Thiopurine methyl-transferase activity and azathioprine metabolite concentrations do not predict clinical outcome in thiopurine-treated inflammatory bowel disease patients

    Alimentary Pharmacology and Therapeutics, Vol. 34, Núm. 5, pp. 544-554